Heart Test Laboratories Inc (NASDAQ:HSCS) shares traded 11.65% higher at $0.19 on Wall Street last session.
In accordance with the data, 1 analysts cover Heart Test Laboratories Inc (NASDAQ:HSCS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $3.80 and a low of $3.80, we find $3.80. Given the previous closing price of $0.17, this indicates a potential upside of 2135.29 percent. HSCS stock price is now -50.69% away from the 50-day moving average and -79.54% away from the 200-day moving average. The market capitalization of the company currently stands at $1.97M.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $3.80 as their price target over the next twelve months.
A total of 30.27% of the company’s stock is owned by insiders.
Heart Test Laboratories Inc (NASDAQ: HSCS) opened at $0.1900 on Monday. During the past 12 months, Heart Test Laboratories Inc has had a low of $0.14 and a high of $3.95. The fifty day moving average price for HSCS is $0.3752 and a two-hundred day moving average price translates $0.9042 for the stock.
The latest earnings results from Heart Test Laboratories Inc (NASDAQ: HSCS) was released for Jul, 2023. According to the Medical Devices Company, earnings per share came in at -$0.13, beating analysts’ expectations of -$0.14 by 0.01. This compares to -$0.28 EPS in the same period last year. The net profit margin was -315273.95% and return on equity was -519.34% for HSCS.
Heart Test Laboratories Inc(HSCS) Company Profile
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor’s offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
